National consumption of opioid and nonopioid analgesics in Croatia: 2007-2013

Darko Krnic, Andrea Anic-Matic, Svjetlana Dosenovic, Pero Draganic, Sasa Zezelic, Livia Puljak, Darko Krnic, Andrea Anic-Matic, Svjetlana Dosenovic, Pero Draganic, Sasa Zezelic, Livia Puljak

Abstract

Background: The increased consumption of analgesics has been documented worldwide during the last 2 decades. The aim of the study was to examine the trends in opioid and nonopioid analgesic consumption in Croatia between 2007 and 2013.

Methods: Data on opioid consumption were extracted from the database of the national authority. All opioid and nonopioid analgesics were included in the analysis. Data were presented as defined daily doses per 1,000 inhabitants per day. Adequacy of opioid consumption was calculated using adequacy of consumption measure.

Results: During the examined 7-year period, the total consumption and total cost of all analgesics in Croatia showed continuous increase. In the M01A group (anti-inflammatory and antirheumatic products, nonsteroids), ibuprofen had an exponential increasing trend, and in 2011, it overtook diclofenac consumption. Ibuprofen and diclofenac had the highest consumption also in the M02A group of topical products for joint and muscular pain. Tramadol was by far the most consumed type of opioids (N02A group) and paracetamol in the group of other analgesics and antipyretics (N02B). The adequacy of consumption measure value was 0.19, indicating that Croatia is a country with a low opioid consumption.

Conclusion: Between 2007 and 2013, both consumption of analgesics and their cost in Croatia had an increasing trend. Comparisons with data from other countries, based on the published literature, indicate that analgesic consumption in Croatia is still relatively low. Calculation of the adequacy of opioid consumption indicated that Croatia is a country with low opioid consumption. Further studies are necessary for establishing whether current analgesic consumption in Croatia corresponds to patient needs.

Keywords: adequacy; analgesic agents; drug utilization; pain; prescription opioids.

Figures

Figure 1
Figure 1
Consumption of anti-inflammatory and antirheumatic products, non-steroids (M01A). Note: The values are shown as defined daily doses per 1,000 inhabitants per day (DDD/1,000/day).
Figure 2
Figure 2
Cost by group and total cost of analyzed analgesics. Note: The costs are shown in millions of Croatian kuna. Abbreviation: H RK, Croatian kuna.
Figure 3
Figure 3
Consumption of opioids (N02A). Note: The values are shown as defined daily doses per 1,000 inhabitants per day (DDD/1,000/day).
Figure 4
Figure 4
Consumption of other analgesics and antipyretics (N02B). Note: The values are shown as defined daily doses per 1,000 inhabitants per day (DDD/1,000/day). Abbreviation: ASA, acetylsalicylic acid.
Figure 5
Figure 5
Consumption by group and total consumption of analyzed analgesics. Note: The values are shown as defined daily doses per 1,000 inhabitants per day (DDD/1,000/day).

References

    1. Hamunen K, Laitinen-Parkkonen P, Paakkari P, et al. What do different databases tell about the use of opioids in seven European countries in 2002? Eur J Pain. 2008;12(6):705–715.
    1. De Conno F, Ripamonti C, Brunelli C. Opioid purchases and expenditure in nine western European countries: ‘are we killing off morphine?’. Palliat Med. 2005;19(3):179–184.
    1. Lasinkas M. Master’s Thesis. Kauno Medicinos Universitetas; 2008. [Accessed August 14, 2015]. Trends in the consumption of analgesic drugs in Lithuania iz 2005–2007. Available from: .
    1. Gudin JA. The changing landscape of opioid prescribing: long-acting and extended-release opioid class-wide risk evaluation and mitigation strategy. Ther Clin Risk Manag. 2012;8:209–217.
    1. Stone ME. The fifth vital sign: what we need to know about pain. Libr J. 2002;127(6):131.
    1. World Health Organization WHO Model List of Essential Medicines. 2015. [Accessed August 14, 2015]. Available from:
    1. Aloisi AM, Aurilio C, Bachiocco V, et al. Endocrine consequences of opioid therapy. Psychoneuroendocrinology. 2009;34(suppl 1):S162–S168.
    1. Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther. 2005;7(5):R1046–R1051.
    1. Farrell M. Opiate withdrawal. Addiction. 1994;89(11):1471–1475.
    1. Savage SR. Assessment for addiction in pain-treatment settings. Clin J Pain. 2002;18(4 suppl):S28–S38.
    1. Seya MJ, Gelders SF, Achara OU, Milani B, Scholten WK. A first comparison between the consumption of and the need for opioid analgesics at country, regional, and global levels. J Pain Palliat Care Pharmacother. 2011;25(1):6–18.
    1. WHO World Health Organization Collaborating Centre for Drug Statistics. 2014. [Accessed August 14, 2015]. Available from: .
    1. Pain & Policy Studies Group Opioid Consumption Data. 2015. [Accessed August 14, 2015]. Available from: .
    1. UNDP Human Development Index. 2014. [Accessed August 14, 2015]. Available from: .
    1. Ahonen R, Enlund H, Klaukka T, Martikainen J. Consumption of analgesics and anti-inflammatory drugs in the nordic countries between 1978–1988. Eur J Clin Pharmacol. 1991;41(1):37–42.
    1. Mijatovic V, Calasan J, Horvat O, Sabo A, Tomic Z, Radulovic V. Consumption of non-steroidal anti-inflammatory drugs in Serbia: a comparison with Croatia and Denmark during 2005–2008. Eur J Clin Pharmacol. 2011;67(2):203–207.
    1. Fosbøl EL, Gislason GH, Jacobsen S, et al. The pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people. Pharmacoepidem Drug Saf. 2008;17(8):822–833.
    1. Hudec R, Kriska M, Bozekova L, Foltan V. Comparison of NSAID consumption in Slovakia, Finland and Norway. Bratisl Lek Listy. 2008;109(8):370–373.
    1. McGettigan P, Henry D. Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS Med. 2013;10(2):e1001388.
    1. Lovrek V, Bradamante V, Saric-Medic M, Kovacic M. Analysis of opioids and other analgesics and antipyretics consumption; World Congress of Pharmacy and Pharmaceutical Sciences 63rd International Congress of FIP; Sydney, Australia. September 4–9; 2003.
    1. Duthey B, Scholten W. Adequacy of opioid analgesic consumption at country, global, and regional levels in 2010, its relationship with development level, and changes compared with 2006. J Pain Symptom Manage. 2014;47(2):283–297.
    1. Fredheim OMS, Skurtveit S, Breivik H, Borchgrevink PC. Increasing use of opioids from 2004 to 2007-Pharmacoepidemiological data from a complete national prescription database in Norway. Eur J Pain. 2010;14(3):289–294.
    1. Fischer B, Jones W, Rehm J. Trends and changes in prescription opioid analgesic dispensing in Canada 2005–2012: an update with a focus on recent interventions. BMC Health Serv Res. 2014;14:90.
    1. Rhodin A. The rise of opiophobia: is history a barrier to prescribing? J Pain Palliat Care Pharmacother. 2006;20(3):31–32.
    1. Fadare JO, Agboola SM, Opeke OA, Alabi RA. Prescription pattern and prevalence of potentially inappropriate medications among elderly patients in a Nigerian rural tertiary hospital. Ther Clin Risk Manag. 2013;9:115–120.
    1. Manchikanti L, Atluri S, Hansen H, et al. Opioids in chronic noncancer pain: have we reached a boiling point yet? Pain Physician. 2014;17(1):E1–E10.
    1. De Lima L, Pastrana T, Radbruch L, Wenk R. Cross-sectional pilot study to monitor the availability, dispensed prices, and affordability of opioids around the globe. J Pain Symptom Manage. 2014;48(4):649–659. e641.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다